Open Access

Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer

  • Authors:
    • Chittibabu Vatte
    • Ali Mohammed Al Amri
    • Cyril Cyrus
    • Shahanas Chathoth
    • Ahmed Alsayyah
    • Arafat Ahmad
    • Mohammed Shakil Akhtar
    • Nada Fehaid Alrashidi
    • Nithya Jayaseeli
    • Hamed Al Wadani
    • Alhussain Al Zahrani
    • Amein Kadhem Al Ali
  • View Affiliations

  • Published online on: July 4, 2019     https://doi.org/10.3892/ol.2019.10565
  • Pages: 2427-2433
  • Copyright : © Vatte et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the major causes of female morbidity and mortality, accounting for ~25% of the total cancer cases in women. Phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic α subunit (PIK3CA) mutations serve a major role in downstream signaling of receptor tyrosine kinases. The present study aimed to elucidate the frequency of exon 9 and 20 mutations of PIK3CA and their role in disease progression. A total of 118 tumor samples from confirmed breast cancer patients were collected from the histopathology laboratory at King Fahd Hospital of the University (Al‑Khobar, Saudi Arabia). Sanger sequencing was performed on extracted DNA to identify the mutations on exons 9 and 20 of PIK3CA. The results were further validated by competitive allele‑specific TaqMan polymerase chain reaction. Three mutations, namely E542K and E545K within exon 9, and H1047R within exon 20, were observed in 25 patients (21.2%). Among these, 18 patients carried the H1047R mutation of the kinase domain, while the remaining 7 patients carried mutations in the helical domain. PIK3CA mutations were associated with the estrogen receptor‑positive/progesterone receptor‑positive (ER+/PR+) group of tumors in contrast to the ER‑/PR‑ group (P=0.021). Furthermore, it was observed that the PIK3CA mutation was associated with a poor disease prognosis. Taken together, the current study emphasized the potential of PIK3CA mutations as an important biomarker for breast cancer classification and the possible use of PIK3CA inhibitor as targeted therapy for breast cancer.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Vatte, C., Al Amri, A.M., Cyrus, C., Chathoth, S., Alsayyah, A., Ahmad, A. ... Al Ali, A.K. (2019). Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer. Oncology Letters, 18, 2427-2433. https://doi.org/10.3892/ol.2019.10565
MLA
Vatte, C., Al Amri, A. M., Cyrus, C., Chathoth, S., Alsayyah, A., Ahmad, A., Akhtar, M. S., Alrashidi, N. F., Jayaseeli, N., Al Wadani, H., Al Zahrani, A., Al Ali, A. K."Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer". Oncology Letters 18.3 (2019): 2427-2433.
Chicago
Vatte, C., Al Amri, A. M., Cyrus, C., Chathoth, S., Alsayyah, A., Ahmad, A., Akhtar, M. S., Alrashidi, N. F., Jayaseeli, N., Al Wadani, H., Al Zahrani, A., Al Ali, A. K."Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer". Oncology Letters 18, no. 3 (2019): 2427-2433. https://doi.org/10.3892/ol.2019.10565